Immune-mediated adverse drug reactions of grade 3–4 occur in up to 2% in the standard organ classes (according to MedDRA).
Early diagnosis and treatment is a key to manage immune-mediated adverse events.
Most immune-related adverse events are clinically well-manageable by use of systemic corticosteroids.
Anti-PD-1 therapy restart is indicated after recovery of events of mild or moderate severity.